| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
LIEGE, Belgium—To determine intestinal absorption of drug candidates, researchers often rely on in vitro assays using Caco-2 cells. Unfortunately, there is some argument on whether the assay truly mimics in vivo behavior in the absence of mucin-generating cells.
 
To address this issue, researchers at the University of Liege and Catholic University of Louvain recently co-cultured Caco-2 cells with mucin-producing HT29-5M21 cells and monitored their behavior in serum-free medium. They described their work in BMC Cell Biology.
 
Based on the expression of genetic markers, the researchers determined that co-culturing the cells did not change the phenotype of the cells. Furthermore, they found that co-cultured cells showed increased paracellular permeability to small molecules that correlated with the proportion of HT29 cells over Caco-2 cells. The researchers plan to use the assay to model human diseases such as celiac disease, which involves altered permeability.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A blue x-ray style image of a human body is shown with the liver illuminated in orange against a dark blue background.

Harnessing liver-on-a-chip models for drug safety

Discover how researchers leverage microphysiological systems in toxicology studies.  
A person wearing a white lab coat types on a laptop with various overlaid enlarged files shown with plus signs on file folders floating over the laptop screen with a clinical lab shown in the background in grey and white tones.

Enhancing bioanalytical studies with centralized data management

Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
A 3D-rendered digital illustration of a molecular structure floating among red blood cells in a bloodstream environment.

Explained: How are metabolite biomarkers improving drug discovery and development?

By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue